Sort
82,697 grants matching “vaccine development”
Novel TLR7/8 agonists as adjuvants for rapid-acting vaccines
$1,078,434David Johnson · Corixa Corporation · N01 · FY2012 · AI
Cancer Prevention-Interception Against MGUS Progression
$1,078,336Yong Li · Baylor College Of Medicine · U54 · FY2024 · CA
BABOON RESEARCH RESOURCE PROGRAM
$1,078,077University Of Oklahoma Hlth Sciences Ctr · P40 · FY2005 · RR
Broad Spectrum Neutralizing Human Abs to SARS and Related Coronaviruses
$1,078,057Wayne A. Marasco · Dana-Farber Cancer Inst · R01 · FY2014 · AI
Epigenetic & Post-Translational Mechanisms of Macrophage Resistance to Mycobacterium tuberculosis During HIV Co-Infection
$1,077,894Thomas R Hawn · University Of Washington · R61 · FY2018 · AI
GLOBAL HIV VACCINE ENTERPRISE
$1,077,813Bill Snow · Global Hiv Vaccine Enterprise · N01 · FY2013 · AI
Vaccine development and production
$1,077,795Sylvain Fleury · University Of Louisiana At Lafayette · U19 · FY2021 · AI
Conjugate Anthrax Vaccine with Dual Virulence Factor Specificity
$1,077,395Lallan Giri · Biologics Resources, Llc · R01 · FY2016 · AI
Core B: Data Management and Analysis
$1,077,339Steven H. Kleinstein · Yale University · U19 · FY2021 · AI
CoVPN 3001 A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine LC3
$1,077,287Margaret Juliana McElrath · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI
Seattle Clinical Trials Unit
$1,077,209Margaret Juliana McElrath · Fred Hutchinson Cancer Center · UM1 · FY2025 · AI
Development and Production of Anti-Malarial Biologicals
$1,077,167Jason Gall · National Institute Of Allergy And Infectious Diseases · ZIB · FY2020 · AI
Human Papillomavirus (HPV) Natural History, Genomics and Risk Assessment
$1,076,966Mark Schiffman · Division Of Cancer Epidemiology And Genetics · ZIA · FY2013 · CA
Clinical and mechanistic studies defining optimal preparative approaches to infants with IL2RG/JAK3/RAG1/RAG2 SCID: a randomized trial of busulfan dosage
$1,076,893Jeffery J Auletta · National Marrow Donor Program · U01 · FY2025 · AI
Optimization and preclinical development of a TB Multiple Antigen Presenting System (MAPS) vaccine
$1,076,287Richard Malley · Boston Children'S Hospital · R01 · FY2019 · AI
Accelerated public health and biomedical research on priority public health objectives through collaboration between US NIH and WHO
$1,076,181Martin Friede · World Health Organization · U01 · FY2019 · AI
Immunotherapy for Malignant Mesothelioma, Lung Cancer and Thymic Malignancies
$1,075,984Raffit Hassan · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Neutralizing Botulinum Neurotoxin with Human Antibodies
$1,075,856Rae Lyn Burke · Sri International · U01 · FY2008 · AI
Immunity to novel T/F SHIVs: variability in the co-evolution of virus and host immunity
$1,075,751Garnett H Kelsoe · Duke University · R01 · FY2017 · AI
PRECLINICAL ASSAYS TO PREDICT TETRAVALENT DENGUE VACCINE EFFICACY
$1,075,722Aravinda M De Silva · Univ Of North Carolina Chapel Hill · R01 · FY2020 · AI
Natural infection of norovirus and sapovirus in a birth cohort in a Peruvian periurban community
$1,075,705Robert H Gilman · Johns Hopkins University · R01 · FY2017 · AI
Virus biology scientific research support component
$1,075,630Beatrice H Hahn · Duke University · UM1 · FY2017 · AI
Administrative Core
$1,075,604Shan Lu · Univ Of Massachusetts Med Sch Worcester · U19 · FY2012 · AI
Effects of genetic polymorphism in MHC, KIR, and related loci on human disease
$1,075,525Mary N. Carrington · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Vaccines and Therapeutics for Nipah and Hendra virus
$1,075,508Christopher Broder · Henry M. Jackson Fdn For The Adv Mil/Med · U01 · FY2009 · AI